However, when combined with LD, anti-PD-1 immunotherapy led to a better efficacy by reducing tumor volume than the control treatment (P = 0.027 for MOC1+LD +αPD-1 vs. MOC1+LD+IgG and P = 0.111 for LD+MOC1+αPD-1 vs. LD+MOC1+IgG; Fig. 1C). This evidence concerns the gene PDCD1 and neoplasm.